“…3 However, REQUITE which is an ongoing multicenter prospective observational study attempts to validate potential biomarkers in order to develop clinically useful statistical models to predict patient's risk of developing long-term side effects following radiation therapy alongside clinical and treatment planning parameters. 33,140 Several biomarkers (BRCA1/2, ATM, RAD51, nibrin (NBN), TP53, Cdh1, XRCC1/2/3, APE1, CHEK2, MLH1, MSH2/3, PTEN, EpCAM, FLCN) 1,[36][37][38][40][41][42][43][44][45][46][56][57][58][59]80,[141][142][143][144][145][146][147][148][149][150][151] have been identified for use in the field of radiation genomics and some are briefly presented here.…”